173 related articles for article (PubMed ID: 23374507)
1. Identification of active Plasmodium falciparum calpain to establish screening system for Pf-calpain-based drug development.
Soh BY; Song HO; Lee Y; Lee J; Kaewintajuk K; Lee B; Choi YY; Cho JH; Choi S; Park H
Malar J; 2013 Feb; 12():47. PubMed ID: 23374507
[TBL] [Abstract][Full Text] [Related]
2. Antimalarial effect of N-acetyl-L-Leucyl-L-leucyl-L-norleucinal by the inhibition of Plasmodium falciparum Calpain.
Jung SY; Zheng B; Choi YY; Soh BY; Kim SY; Park KI; Park H
Arch Pharm Res; 2009 Jun; 32(6):899-906. PubMed ID: 19557368
[TBL] [Abstract][Full Text] [Related]
3. Confocal microscopic findings of cysteine protease calpain in Plasmodium falciparum.
Choi YY; Jung SY; Cho PY; Soh BY; Zheng B; Kim SY; Park KI; Park H
Exp Parasitol; 2010 Mar; 124(3):341-5. PubMed ID: 19861123
[TBL] [Abstract][Full Text] [Related]
4. Potential Interaction of Plasmodium falciparum Hsp60 and Calpain.
Yeo SJ; Liu DX; Park H
Korean J Parasitol; 2015 Dec; 53(6):665-73. PubMed ID: 26797432
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and evaluation of peptidyl α,β-unsaturated carbonyl derivatives as anti-malarial calpain inhibitors.
Mallik SK; Li DY; Cui M; Song HO; Park H; Kim HS
Arch Pharm Res; 2012 Mar; 35(3):469-79. PubMed ID: 22477194
[TBL] [Abstract][Full Text] [Related]
6. BDA-410: a novel synthetic calpain inhibitor active against blood stage malaria.
Li X; Chen H; Jeong JJ; Chishti AH
Mol Biochem Parasitol; 2007 Sep; 155(1):26-32. PubMed ID: 17583361
[TBL] [Abstract][Full Text] [Related]
7. A novel approach for the discovery of chemically diverse anti-malarial compounds targeting the Plasmodium falciparum Coenzyme A synthesis pathway.
Fletcher S; Avery VM
Malar J; 2014 Aug; 13():343. PubMed ID: 25174342
[TBL] [Abstract][Full Text] [Related]
8. Specific calpain activity evaluation in Plasmodium parasites.
Gomes MM; Budu A; Ventura PD; Bagnaresi P; Cotrin SS; Cunha RL; Carmona AK; Juliano L; Gazarini ML
Anal Biochem; 2015 Jan; 468():22-7. PubMed ID: 25281458
[TBL] [Abstract][Full Text] [Related]
9. Deletion of the parasite-specific insertions and mutation of the catalytic triad in glutathione reductase from chloroquine-sensitive Plasmodium falciparum 3D7.
Gilberger TW; Schirmer RH; Walter RD; Müller S
Mol Biochem Parasitol; 2000 Apr; 107(2):169-79. PubMed ID: 10779594
[TBL] [Abstract][Full Text] [Related]
10. Transgenic Plasmodium parasites stably expressing Plasmodium vivax dihydrofolate reductase-thymidylate synthase as in vitro and in vivo models for antifolate screening.
Somsak V; Uthaipibull C; Prommana P; Srichairatanakool S; Yuthavong Y; Kamchonwongpaisan S
Malar J; 2011 Oct; 10():291. PubMed ID: 21981896
[TBL] [Abstract][Full Text] [Related]
11. Specific inhibition of the aspartate aminotransferase of Plasmodium falciparum.
Wrenger C; Müller IB; Schifferdecker AJ; Jain R; Jordanova R; Groves MR
J Mol Biol; 2011 Jan; 405(4):956-71. PubMed ID: 21087616
[TBL] [Abstract][Full Text] [Related]
12. An alpha-proteobacterial type malate dehydrogenase may complement LDH function in Plasmodium falciparum. Cloning and biochemical characterization of the enzyme.
Tripathi AK; Desai PV; Pradhan A; Khan SI; Avery MA; Walker LA; Tekwani BL
Eur J Biochem; 2004 Sep; 271(17):3488-502. PubMed ID: 15317584
[TBL] [Abstract][Full Text] [Related]
13. Plasmodium falciparum carbonic anhydrase is a possible target for malaria chemotherapy.
Reungprapavut S; Krungkrai SR; Krungkrai J
J Enzyme Inhib Med Chem; 2004 Jun; 19(3):249-56. PubMed ID: 15499996
[TBL] [Abstract][Full Text] [Related]
14. Plasmodium falciparum glutaredoxin-like proteins.
Deponte M; Becker K; Rahlfs S
Biol Chem; 2005 Jan; 386(1):33-40. PubMed ID: 15843145
[TBL] [Abstract][Full Text] [Related]
15. The calpain domain of the maize DEK1 protein contains the conserved catalytic triad and functions as a cysteine proteinase.
Wang C; Barry JK; Min Z; Tordsen G; Rao AG; Olsen OA
J Biol Chem; 2003 Sep; 278(36):34467-74. PubMed ID: 12824178
[TBL] [Abstract][Full Text] [Related]
16. Identification of Collateral Sensitivity to Dihydroorotate Dehydrogenase Inhibitors in Plasmodium falciparum.
Ross LS; Lafuente-Monasterio MJ; Sakata-Kato T; Mandt REK; Gamo FJ; Wirth DF; Lukens AK
ACS Infect Dis; 2018 Apr; 4(4):508-515. PubMed ID: 29336544
[TBL] [Abstract][Full Text] [Related]
17. Chemoprotective antimalarials identified through quantitative high-throughput screening of Plasmodium blood and liver stage parasites.
Dorjsuren D; Eastman RT; Wicht KJ; Jansen D; Talley DC; Sigmon BA; Zakharov AV; Roncal N; Girvin AT; Antonova-Koch Y; Will PM; Shah P; Sun H; Klumpp-Thomas C; Mok S; Yeo T; Meister S; Marugan JJ; Ross LS; Xu X; Maloney DJ; Jadhav A; Mott BT; Sciotti RJ; Winzeler EA; Waters NC; Campbell RF; Huang W; Simeonov A; Fidock DA
Sci Rep; 2021 Jan; 11(1):2121. PubMed ID: 33483532
[TBL] [Abstract][Full Text] [Related]
18. Plasmodium falciparum protein kinase as a potential therapeutic target for antimalarial drugs development.
Mahmud F; Lee PC; Abdul Wahab H; Mustaffa KMF; Leow CH; Azhar R; Lai NS
Trop Biomed; 2020 Sep; 37(3):822-841. PubMed ID: 33612795
[TBL] [Abstract][Full Text] [Related]
19. Structural analysis of chorismate synthase from Plasmodium falciparum: a novel target for antimalaria drug discovery.
Tapas S; Kumar A; Dhindwal S; Preeti ; Kumar P
Int J Biol Macromol; 2011 Nov; 49(4):767-77. PubMed ID: 21801743
[TBL] [Abstract][Full Text] [Related]
20. Recombinant plasmepsin 1 from the human malaria parasite plasmodium falciparum: enzymatic characterization, active site inhibitor design, and structural analysis.
Liu P; Marzahn MR; Robbins AH; Gutiérrez-de-Terán H; Rodríguez D; McClung SH; Stevens SM; Yowell CA; Dame JB; McKenna R; Dunn BM
Biochemistry; 2009 May; 48(19):4086-99. PubMed ID: 19271776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
